Eversheds Sutherland has advised Peptonic Medical AB ("Peptonic") on its merger with Pharmiva AB (publ). The merger is one of the few mergers between two listed companies completed in 2023.
Peptonic is an innovative Swedish biomedical company engaged in research, development, and sales of unique medical treatments in the field of women's intimate health. Under the brand VagiVital®, the product portfolio encompasses treatments for various conditions such as vaginal atrophy, bacterial vaginosis, and urinary tract infections. These clinically tested products address the growing demand for intimate self-care within the business concept of Diagnose, Treat, Prevent. Sweden serves as the reference market to facilitate geographic expansion in collaboration with local distributors. The United States is the largest market in terms of sales. The company is headquartered in Stockholm, Sweden, with a sales office in New York, NY, and an R&D unit in Caesarea, Israel. Peptonic also has a wholly owned subsidiary, Lune Oy, in Finland, focusing on sustainable period products sold under the Lunette®ď¸Ź brand (www.lunette.com).
Peptonic is listed on Spotlight Stock Market, ticker: PMED.
Eversheds Sutherland’s team consisted of Mark Falkner, Andreas Vestberg and John Edgren. Mangold Fondkommission AB acted as financial advisor to Peptonic.
The materials on the Eversheds Sutherland website are for general information purposes only and do not constitute legal advice. While reasonable care is taken to ensure accuracy, the materials may not reflect the most current legal developments. Eversheds Sutherland disclaims liability for actions taken based on the materials. Always consult a qualified lawyer for specific legal matters. To view the full disclaimer, see our Terms and Conditions or Disclaimer section in the footer. Eversheds Sutherland is a provider of legal and other services operating through various separate and distinct legal entities. For further information about these entities and Eversheds Sutherlands' structure please see the Legal Notice page of this website.